bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
SOMERVILLE, Mass., November 14, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September 30,
Bluebird bio Inc., which nine years ago was worth nearly as much as the airline JetBlue, said it's now looking for enough ...
We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we ...
bluebird bio is to ask regulators to restart clinical studies of its LentiGlobin for sickle cell disease, after an investigation concluded that a case of acute myeloid leukaemia (AML) was "very ...
Welcome to bluebird bio's third quarter 2024 results conference call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer ...
Bluebird Bio (BLUE) Company Description: bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic ...
US biotech bluebird bio has announced plans to split into two ... While bluebird has conducted pioneering work in gene therapy for blood disorders and in cancer cell therapy, products have ...
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that new and updated data from its lentiviral vector (LVV) gene addition programs in patients with sickle ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback